Indian pharmaceutical exports crossed $30 billion in fiscal 25, with 31% surge in March

File images are for representation purposes only. |Photo source: Reuters

India’s annual drug and drug exports involved a record $30 billion, up 31% in March by fiscal 23.

The export volume was $332 million, 9.39% higher than the $2785.17 billion export, according to official trade data recently released.

Pharma Exports hit $30 billion for the first time. Raja Bhanu, Director-General of Pharmaceuticals’ Export Promotion Committee, said the target for the fiscal year 25 is US$29.38 billion.

March performance

The March performance stands out financially, even as India continues to work hard to capitalize on and build new markets, it will be commemorated by the development of the United States. If the U.S. initially put forward some hope in the fiscal year, by the end of the year, Donald Trump, president of the reciprocal 26% tariff, threatened to introduce it, which would lead to exporters scrambling to ship shipments. However, Pharma is not on the list of items that have been declared taxable and put on hold for 90 days.

Pharma export rate rose 31.21% in March to $381.51 million ($280.571 million). The next best performance for the fiscal period was in January, when exports rose 21.47% to $259.88 million ($213.29.2 million). May was another month when growth hit double-digit numbers (10.63% to $230.56 million), while February was the only month of signing, with 1.52% to $247.42 million).

In addition to the U.S. factor, FY25 exports face geopolitical tensions, economic slowdowns and logistical challenges.

Product Category

Pharmexcil DG said it was waiting for the pellet details in March. Data from April 5 showed that drug formula and biology, as product categories, resulted in US$201.1818 billion, accounting for more than 75% of total exports. The category grew by nearly 9%.

In 11 months, bulk drug and drug intermediates were exported the highest, up 1.40% to $431.93 million. Despite the third largest export category, vaccine export value in pharmaceutical products fell 4.20% to $104.37 million.

Exports of surgical operations rose by 5.16%, with export value of $684.7 million. Ayush and Herbal product exports rose 6.17% to $620.97 million. The total fiscal amount reached 6.95%, reaching $695,569 million.

Top U.S. Markets

The United States has remained the largest market for years and now maintains its former power that accounts for more than a third of India’s pharmaceutical exports. From a value perspective, U.S. exports increased by 14.29%, at $895.37 million ($783.3 million). The United Kingdom, Brazil, France and South Africa are the others in the top five countries, accounting for less than 10.5% of exports.

Also Read: Tariffs on U.S. Cars Put in Focus on Indian Pharma

Despite a 1.78% contraction in exports, South Africa is still found on the list. The top 25 countries with declines in exports over the 11 months of fiscal year were the United Arab Emirates (down 17.70%); Turkey (16%); Sri Lanka (14.60%); Netherlands (13.79%), China (10.60%) and Belgium (7.37%). Official data showed that Mexico’s exports fell to 3.80%, while Thailand’s exports fell to 0.14%.

Top area

Regions, NAFTA, Europe, Africa and LAC are four major regions, accounting for 76% of India’s pharmaceutical exports. Among them, the North American Free Trade Agreement accounted for 36.60%, and exports increased by 14.06%, to US$980.478 million.

Among the regions with decline in exports, Africa (1.74%) and Northeast Asia (4.30%) were involved.